Results 201 to 210 of about 138,819 (251)

Comprehensive assessment of erenumab efficacy in participants with high-frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study. [PDF]

Headache
Paiva da Silva Lima G, Rao R, Szabó G, Szklener S, Tassorelli C, Nastaj M, Chou DE, Khodavirdi AC, Chehrenama M, Zhu Y, Bhatia AK, Dodick DW.   +11 more
europepmc   +1 more source

Review: An Update on CGRP Monoclonal Antibodies for the Preventive Treatment of Episodic Migraine. [PDF]

Curr Pain Headache Rep
Nicol KS, Burkett JG.
europepmc   +1 more source

Identifying cognitive-affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions. [PDF]

Headache
Fox J, Gaul C, Kuhlencord M, Peperkorn N, Ohse J, Krutzki J, Shiban Y.   +6 more
europepmc   +1 more source

Pathophysiological changes in incentive processing in episodic migraine: a preliminary event-related potential study. [PDF]

Soc Cogn Affect Neurosci
Liu C, Qu Y, Chen G, Ding W, Derrington E, Zhang B, Pei L, Li Y.   +7 more
europepmc   +1 more source

Triggers, Protectors, and Predictors in Episodic Migraine [PDF]

Current Pain and Headache Reports, 2018
A wide variety of triggers prompt attacks in episodic migraine. Although experimental triggers such as glyceryl trinitrate reliably produce migraine, natural triggers are much less predictable and vary in importance between individuals. This review describes the most common triggers in episodic migraine and provides strategies for managing them in ...
Michael J. Marmura
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

Erenumab for episodic migraine

Pain Management, 2022
In this review, the authors provide an overview of erenumab, a monoclonal antibody used for the preventative treatment of episodic migraine by targeting the CGRP pathway. Randomized controlled trials have shown that erenumab is associated with a statistically significant decrease in monthly migraine days in patients with episodic migraine at monthly ...
Abhigyan Datta, Sahil Gupta, Shashi Maryala, Vikram Aggarwal, Pooja Chopra, Sameer Jain   +5 more
openaire   +2 more sources

Episodic Migraine and POTS

Current Pain and Headache Reports, 2023
Migraine is prevalent in patients with postural orthostatic tachycardia syndrome (POTS). The purpose of this review is to summarize and interpret studies that examine stress response systems in patients with migraine, focusing on their relevance to the pathologies associated with POTS.
openaire   +2 more sources

Preventive Treatment for Episodic Migraine

Neurologic Clinics, 2019
Episodic migraine is a debilitating condition. Preventive therapy is used to reduce frequency, duration, or severity of attacks. This review discusses principles of preventive treatment with a focus on preventive treatment options for people with episodic migraine.

exaly   +3 more sources

Episodic Unilateral Mydriasis and Migraine

American Journal of Ophthalmology, 1984
Seven patients (all female, ranging in age from 5 to 53 years) had typical migraine and episodic unilateral mydriasis. These mydriatic episodes, usually occurring during the headache, lasted from 15 minutes to 24 hours and had occurred for three months to 35 years. Three patients had suffered from car sickness as children and there was a family history
D, Woods, P S, O'Connor, R, Fleming
openaire   +2 more sources